Search

-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will [...]

PHILADELPHIA: LAVA Therapeutics N.V.; Seagen Inc. has issued the following news release: Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. [...]

HAMILTON, Bermuda, Sep 12, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:KNSA), EQNX::TICKER_END Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate [...]

London: Oxford BioMedica PLC has issued the following press release: Oxford BioMedica PLC on Wednesday said it signed a license and supply agreement with an unnamed new partner. Shares were [...]

NEW YORK (PRWEB) August 29, 2022 Grid Biosciences ('Grid'), a biotechnology company, today announced the signing of a license agreement for the development of a vaccine against Epstein-Barr virus ('EBV') [...]

Grid Biosciences signs license agreement for the development of a vaccine against Epstein-Barr virus with the National Institute of Allergy and Infectious Diseases. NEW YORK, Aug. 29, 2022 /PRNewswire-PRWeb/ -- [...]

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered [...]

HAMILTON: Kiniksa Pharmaceuticals, Ltd. has issued the following news release: Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across [...]

HAMILTON, Bermuda, Aug 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:KNSA), EQNX::TICKER_END - Kiniksa to receive $100 million in upfront and near-term payments - - Kiniksa is eligible to [...]

M2 PHARMA-April 14, 2023-Pillar Biosciences enters into non-exclusive licensing agreement with Keygene NV (C)2023 M2 COMMUNICATIONS Pillar Biosciences, Inc., a US-based company involved in Decision Medicine, announced on Thursday that [...]

M2 EQUITYBITES-April 14, 2023-Pillar Biosciences enters into non-exclusive licensing agreement with Keygene NV (C)2023 M2 COMMUNICATIONS http://www.m2.co.uk Pillar Biosciences, Inc., a US-based company involved in Decision Medicine, announced on Thursday [...]

M2 PHARMA-February 24, 2023-Lineage Enters Into Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (C)2023 M2 COMMUNICATIONS - US-based biotechnology company [...]

London, United Kingdom: Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with Celltrion, Inc. and Celltrion Healthcare, Inc. (Celltrion) for Yuflyma TM (CT-P17), the first [...]

London: Oxford BioMedica PLC has issued the following press release: Oxford BioMedica PLC on Tuesday said it started a new project and signed a license and supply agreement. The Oxford, [...]

DUBLIN: ERS Genomics has issued the following news release: ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD ('Lepton'). This is a non-exclusive [...]

CHENGDU: Kelun-Biotech has issued the following news release: Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), a clinical-stage biotech company focused on biologic and small molecule discovery and [...]

SAN DIEGO: Replicate Bioscience has issued the following news release: In a move that signifies the heightened focus on mRNA as a key tool in human health, Precision NanoSystems (PNI) [...]

CHENGDU, China, Jul 26, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), a clinical-stage biotech company focused on biologic and [...]

- Companies aim to support development of up to 15 new genomic medicine products - Replicate's commercial licensing of lipid nanoparticle technology from Precision NanoSystems at foundation of deal SAN [...]

License allows Lepton, with their proprietary Castling Technology, to develop and commercialize products and services using CRISPR/Cas9 technology DUBLIN and ZIKHRON YA'AKOV, Israel, July 26, 2022 /PRNewswire/ -- ERS Genomics [...]

Garden City, NY, Jul 21, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:PRPH), EQNX::TICKER_END Confirms Quarterly Growth continues year-over-year Announces significant progress being made in Genomics Business Company to Host [...]

ALAMEDA: Exelixis, Inc. has issued the following news release: Exelixis, Inc. (Nasdaq: EXEL) and Ryvu Therapeutics S.A. ('Ryvu') (Warsaw Stock Exchange: RVU) today announced that the companies have entered into [...]

ALAMEDA, Calif. & KRAKOW, Poland: Exelixis, Inc. and Ryvu Therapeutics S.A. announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies [...]

SAN DIEGO: Dare Bioscience, Inc. has issued the following press release: Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the exclusive license agreement entered [...]

SAN DIEGO, June 30, Jun 30, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:DARE),(NYSE:OGN), EQNX::TICKER_END Dare will receive a $10 million upfront payment from Organon An estimated 21 million American [...]

DURHAM: PRECISION BIOSCIENCES, INC. has issued the following news release: Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in [...]

SHANGHAI and GAITHERSBURG: I-Mab has issued the following news release: I-Mab (the 'Company') (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today [...]

LUND, Sweden: Exelixis, Inc. (Nasdaq: EXEL) and BioInvent International AB (BioInvent) (Nasdaq Stockholm: BINV) today announced that the companies have entered into an option and license agreement focused on the [...]

- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening platform and antibody library - ALAMEDA, [...]

PLANEGG: MorphoSys AG has issued the following news release: MorphoSys AG (FSE: MOR; NASDAQ: MOR) and Human Immunology Biosciences, Inc. (HIBio), a South San Francisco-based biotechnology company focused on discovering [...]

Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide [...]

--Through a partnership with antisense pioneer Agrawal's Arnay Sciences, Alloy strengthens its mission to democratize enabling drug discovery technology for the global scientific community-- BOSTON -- Alloy Therapeutics, a biotechnology [...]

TUEBINGEN: Immatics N.V. (Nasdaq: IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, Editas Medicine), a [...]

TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Jun 07, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:EDIT), EQNX::TICKER_END Immatics N.V. (Nasdaq: IMTX, 'Immatics'), a clinical-stage biopharmaceutical company active in the discovery [...]

AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2, the virus that causes COVID-19. Under [...]

M2 PRESSWIRE-May 18, 2022-: AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19 (C)1994-2022 M2 COMMUNICATIONS RDATE:17052022 AstraZeneca has entered into a licence agreement with RQ Biotechnology [...]

DUBLIN, May 9, 2022 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/2907758/global-co-development-partnering-terms-and?utm_source=CI&utm_medium=PressRelease&utm_code=5xtwbr&utm_campaign=1695659+-+Unprecedented+Access+to+the+Co-Development+Deals+and+Agreements+Entered+Into+By+the+Worlds+Leading+Life+Science+Companies%2c+2015-2022&utm_exec=chdo54prd report has been added toResearchAndMarkets.com's offering. The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive [...]

SOUTH SAN FRANCISCO, Calif. -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it [...]

2023 JAN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling [...]

M2 PHARMA-January 9, 2023-Fosun Pharma signs exclusive license agreement with Shanghai Henlius Biotech (C)2023 M2 COMMUNICATIONS Fosun Pharma (600196.SH, 02196.HK), a global pharmaceutical and healthcare industry group deep-rooted in China, [...]

M2 EQUITYBITES-January 9, 2023-Fosun Pharma signs exclusive license agreement with Shanghai Henlius Biotech (C)2023 M2 COMMUNICATIONS http://www.m2.co.uk Fosun Pharma (600196.SH, 02196.HK), a global pharmaceutical and healthcare industry group deep-rooted in [...]

M2 EQUITYBITES-January 5, 2023-Synaffix enters into Hummingbird Bioscience licensing agreement (C)2023 M2 COMMUNICATIONS http://www.m2.com Synaffix BV, a Dutch biotechnology company, announced on Wednesday that it has entered into a licensing [...]

M2 PHARMA-January 5, 2023-Synaffix enters into Hummingbird Bioscience licensing agreement (C)2023 M2 COMMUNICATIONS Synaffix BV, a Dutch biotechnology company, announced on Wednesday that it has entered into a licensing agreement [...]

M2 PHARMA-December 30, 2022-LegoChem Biosciences, Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates (C)2022 M2 COMMUNICATIONS - South Korea-based biotechnology company LegoChem [...]

M2 PHARMA-November 9, 2022-Salipro Biotech signs research collaboration and license agreement with Sanofi (C)2022 M2 COMMUNICATIONS Salipro Biotech AB, a Sweden-based biotech company, announced on Tuesday that it has signed [...]

M2 EQUITYBITES-November 9, 2022-Salipro Biotech signs research collaboration and license agreement with Sanofi (C)2022 M2 COMMUNICATIONS http://www.m2.com Salipro Biotech AB, a Sweden-based biotech company, announced on Tuesday that it has [...]

M2 PHARMA-November 2, 2022-CSL signs collaboration and license agreement with Arcturus Therapeutics Holdings (C)2022 M2 COMMUNICATIONS CSL Limited (ASX: CSL) (USOTC: CSLLY), an Australia-based global biotechnology company, announced on Tuesday [...]

M2 EQUITYBITES-November 2, 2022-CSL signs collaboration and license agreement with Arcturus Therapeutics Holdings (C)2022 M2 COMMUNICATIONS http://www.m2.com CSL Limited (ASX: CSL) (USOTC: CSLLY), an Australia-based global biotechnology company, announced on [...]

Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics Transaction includes worldwide exclusive rights for development and commercialization in all fields of use NEW YORK, April [...]

(GLOBE NEWSWIRE via COMTEX) -- - Exclusive collaboration combines BioNTech's mRNA vaccine development expertise and Matinas' Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines, including [...]